Direct-Acting Antivirals

Cross-source consensus on Direct-Acting Antivirals from 1 sources and 5 claims.

1 sources · 5 claims

Dosage & preparation

All eligible participants are offered sofosbuvir 400 mg plus velpatasvir 100 mg once daily for 12 weeks. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
Participants receive a first 4-week bottle of sofosbuvir/velpatasvir if eligible. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
Drug-drug interactions with sofosbuvir/velpatasvir are checked using the Liverpool HEP Interactions resource. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
Generic pan-genotypic direct-acting antiviral treatment is available at much lower cost than previously. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol
Missed doses may be addressed by adding treatment weeks at clinician discretion with principal investigator consultation. — Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol